1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Glomerulonephritis Disease Overview

3. Glomerulonephritis R&D Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Glomerulonephritis Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Glomerulonephritis Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Glomerulonephritis companies
6.1.1. Business Profile
6.1.2. Pipeline Products
6.1.3. Glomerulonephritis Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services

Companies mentioned
Achillion Pharmaceuticals Inc, Alexion Pharmaceuticals Inc, Algomedix Inc, Amyndas Pharmaceuticals LLC, Apellis Pharmaceuticals Inc, Avexxin AS, Biogen Inc, Calliditas Therapeutics AB, ChemoCentryx Inc, Complexa Inc, Cytodesign Inc, Dimerix Bioscience Pty Ltd, Ergon Pharmaceuticals LLC, Goldfinch Biopharma Inc, Kyowa Hakko Kirin Co Ltd, Merck KGaA, Novartis AG, Omeros Corporation, Oraxion Therapeutics Inc, Pfizer Inc, Polyneuron Pharmaceuticals AG, Ra Pharmaceuticals Inc, Reata Pharmaceuticals Inc, Retrophin Inc, Rigel Pharmaceuticals Inc, Sarfez Pharmaceuticals Inc, Shire Plc, Sujana Biotech, LLC, Variant Pharmaceuticals Inc, Visterra Inc